1285515-21-0 Usage
Description
LRRK2-kinase inhibitor, specifically GSK2578215A, is a potent and selective inhibitor of the leucine-rich repeat kinase 2 (LRRK2) enzyme. It has emerged as a promising therapeutic agent for the treatment of Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons.
Uses
Used in Pharmaceutical Industry:
LRRK2-kinase inhibitor is used as a therapeutic agent for the treatment of Parkinson's disease. It targets the LRRK2 enzyme, which has been implicated in the pathogenesis of the disease. By inhibiting the activity of LRRK2, GSK2578215A aims to slow down or halt the progression of Parkinson's disease, thereby improving the quality of life for patients.
In addition to its primary application in treating Parkinson's disease, LRRK2-kinase inhibitors may also have potential uses in other areas of medicine, such as in the development of diagnostic tools or as research tools for studying the role of LRRK2 in various biological processes. However, further research and clinical trials are necessary to fully explore and validate these potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1285515-21-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,5,5,1 and 5 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1285515-21:
(9*1)+(8*2)+(7*8)+(6*5)+(5*5)+(4*1)+(3*5)+(2*2)+(1*1)=160
160 % 10 = 0
So 1285515-21-0 is a valid CAS Registry Number.
1285515-21-0Relevant articles and documents
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
Ding, Xiao,Dai, Xuedong,Long, Kai,Peng, Cheng,Andreotti, Daniele,Bamborough, Paul,Eatherton, Andrew J.,Edge, Colin,Jandu, Karamjit S.,Nichols, Paula L.,Philps, Oliver J.,Stasi, Luigi Piero,Wan, Zehong,Xiang, Jia-Ning,Dong, Kelly,Dossang, Pamela,Ho, Ming-Hsun,Li, Yi,Mensah, Lucy,Guan, Xiaoming,Reith, Alastair D.,Ren, Feng
, p. 4034 - 4038 (2017/08/23)
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.
